Selective targeting of dipeptidyl‐peptidase 4 (DPP‐4) positive senescent chondrocyte ameliorates osteoarthritis progression
Aging Cell · 2024
DOI: 10.1111/acel.14161 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, 2024. Verfasst von Du Hyun Ro und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Chondrocytes, Osteoarthritis, Dipeptidyl Peptidase 4, Cellular Senescence. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Senescent cells increase in many tissues with age and induce age‐related pathologies, including osteoarthritis (OA). Senescent chondrocytes (SnCs) are found in OA cartilage, and the clearance of those chondrocytes prevents OA progression. However, targeting SnCs is challenging due to the absence of a senescent chondrocyte‐specific marker. Therefore, we used flow cytometry to screen and select senescent chondrocyte surface markers and cross‐validated with published transcriptomic data. Chondrocytes expressing dipeptidyl peptidase‐4 (DPP‐4), the selected senescent chondrocyte‐specific marker, had multiple senescence phenotypes, such as increased senescence‐associated‐galactosidase, p16, p21, and senescence‐associated secretory phenotype expression, and showed OA chondrocyte phenotypes. To examine the effects of DPP‐4 inhibition on DPP‐4+ SnCs, sitagliptin, a DPP‐4 inhibitor, was treated in vitro. As a result, DPP‐4 inhibition selectively eliminates DPP‐4+ SnCs without affecting DPP‐4‐ chondrocytes. To assess in vivo therapeutic efficacy of targeting DPP‐4+ SnCs, three known senolytics (ABT263, 17DMAG, and metformin) and sitagliptin were comparatively verified in a DMM‐induced rat OA model. Sitagliptin treatment specifically and effectively eliminated DPP‐4+ SnCs, compared to the other three senolytics. Furthermore, Intra‐articular sitagliptin injection to the rat OA model increased collagen type II and proteoglycan expression and physical functions and decreased cartilage destruction, subchondral bone plate thickness and MMP13 expression, leading to the amelioration of OA phenotypes. Collectively, OARSI score was lowest in the sitagliptin treatment group. Taken together, we verified DPP‐4 as a surface marker for SnCs and suggested that the selective targeting of DPP‐4+ chondrocytes could be a promising strategy to prevent OA progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Seoul National University College of Medicine, Seoul, Korea.
- Laboratory for Cellular Response to Oxidative Stress, Cell2in, Inc., Seoul, Korea.
- Department of Orthopedic Surgery, Seoul National University Hospital, Seoul, Korea.
ORCID-Profile: Du Hyun Ro, Gun Hee Cho, Ji Yoon Kim, Seong Ki Min, Hyun Cheol Bae, Hyuk-Soo Han
Zitieren
APA
Ro, D. H., Cho, G. H., Kim, J. Y., Min, S. K., Yang, H. R., Park, H. J., Wang, S. Y., Kim, Y. J., Lee, M. C., Bae, H. C., & Han, H. S. (2024). Selective targeting of dipeptidyl‐peptidase 4 (DPP‐4) positive senescent chondrocyte ameliorates osteoarthritis progression. Aging Cell. https://doi.org/10.1111/acel.14161
Vancouver
Ro DH, Cho GH, Kim JY, Min SK, Yang HR, Park HJ, et al. Selective targeting of dipeptidyl‐peptidase 4 (DPP‐4) positive senescent chondrocyte ameliorates osteoarthritis progression. Aging Cell. 2024. doi:10.1111/acel.14161
BibTeX
@article{Ro2024,
author = {Ro, Du Hyun and Cho, Gun Hee and Kim, Ji Yoon and Min, Seong Ki and Yang, Ha Ru and Park, Hee Jung and Wang, Sun Young and Kim, You Jung and Lee, Myung Chul and Bae, Hyun Cheol and Han, Hyuk-Soo},
title = {Selective targeting of dipeptidyl‐peptidase 4 (DPP‐4) positive senescent chondrocyte ameliorates osteoarthritis progression},
journal = {Aging Cell},
year = {2024},
doi = {10.1111/acel.14161}
}
EUVIMED